These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21748427)

  • 1. Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute.
    Qi WX; He AN; Tang LN; Shen Z; Yao Y
    Med Oncol; 2012 Sep; 29(3):2229-33. PubMed ID: 21748427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
    Yu W; Tang L; Lin F; Yao Y; Shen Z
    Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.
    Huang YJ; He AN; Sun YJ; Shen Z; Min DL; Yao Y
    Asian Pac J Cancer Prev; 2015; 16(6):2391-5. PubMed ID: 25824770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.
    He A; Qi W; Huang Y; Sun Y; Shen Z; Zhao H; Yang Y; Yao Y
    Int J Clin Oncol; 2013 Jun; 18(3):498-505. PubMed ID: 22534798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.
    Qi WX; He AN; Tang LN; Shen Z; Lin F; Yao Y
    Jpn J Clin Oncol; 2012 May; 42(5):427-31. PubMed ID: 22450929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
    Lewis IJ; Nooij MA; Whelan J; Sydes MR; Grimer R; Hogendoorn PC; Memon MA; Weeden S; Uscinska BM; van Glabbeke M; Kirkpatrick A; Hauben EI; Craft AW; Taminiau AH; ;
    J Natl Cancer Inst; 2007 Jan; 99(2):112-28. PubMed ID: 17227995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
    Rha SY; Chung HC; Gong SJ; Shim KY; Ahn JB; Yang WI; Shin KH; Yoo NC; Kim JH; Roh JK; Lee CI; Kim BS
    Oncol Rep; 1999; 6(3):631-7. PubMed ID: 10203605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
    Bielack SS; Smeland S; Whelan JS; Marina N; Jovic G; Hook JM; Krailo MD; Gebhardt M; Pápai Z; Meyer J; Nadel H; Randall RL; Deffenbaugh C; Nagarajan R; Brennan B; Letson GD; Teot LA; Goorin A; Baumhoer D; Kager L; Werner M; Lau CC; Sundby Hall K; Gelderblom H; Meyers P; Gorlick R; Windhager R; Helmke K; Eriksson M; Hoogerbrugge PM; Schomberg P; Tunn PU; Kühne T; Jürgens H; van den Berg H; Böhling T; Picton S; Renard M; Reichardt P; Gerss J; Butterfass-Bahloul T; Morris C; Hogendoorn PC; Seddon B; Calaminus G; Michelagnoli M; Dhooge C; Sydes MR; Bernstein M;
    J Clin Oncol; 2015 Jul; 33(20):2279-87. PubMed ID: 26033801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
    Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
    Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
    Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
    Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis.
    Zhao H; Yao Y; Wang Z; Lin F; Sun Y; Chen P
    J Chemother; 2010 Apr; 22(2):119-24. PubMed ID: 20435572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO.
    Blay JY; Penel N; Toulmonde M; Valentin T; Chaigneau L; Rios M; Saada-Bouzid E; Firmin N; Bertucci F; Marec-Berard P; Ray-Coquard I; Lervat C; Rolland F; Thyss A; Conroy T; Brahmi M; Dufresne A; Merrouche Y; Brunat-Mentigny M; Biron P; Bompas E; Perol D;
    Eur J Cancer; 2024 Sep; 208():114228. PubMed ID: 39018632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.
    Navid F; Santana VM; Neel M; McCarville MB; Shulkin BL; Wu J; Billups CA; Mao S; Daryani VM; Stewart CF; Kunkel M; Smith W; Ward D; Pappo AS; Bahrami A; Loeb DM; Reikes Willert J; Rao BN; Daw NC
    Int J Cancer; 2017 Oct; 141(7):1469-1477. PubMed ID: 28631382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
    Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q
    Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
    Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
    Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma.
    Wen XZ; Pan QZ; Xu BS; Xiao W; Weng DS; Zhao JJ; Xu HR; Huang Z; Niu XH; Zhang X
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):209-215. PubMed ID: 35022817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged 14-day continuous infusion of high-dose ifosfamide for patients with relapsed and refractory high-grade osteosarcoma: a retrospective multicentre cohort study.
    Tirtei E; Campello A; Sciannameo V; Asaftei SD; Meazza C; Sironi G; Longhi A; Ibrahim T; Tamburini A; Coccoli L; Crocco F; Cagnazzo C; De Luna E; Quarello P; Berchialla P; Fagioli F
    BMC Cancer; 2024 Jun; 24(1):747. PubMed ID: 38898388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
    Patel SR; Papadopolous N; Raymond AK; Donato M; Seong CM; Yasko AW; Lewis VO; Lin PP; Champlin R; Benjamin RS
    Cancer; 2004 Jul; 101(1):156-63. PubMed ID: 15222001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.